Earnings Call
Apr 28, 2026
Q1 FY2026
EPS Estimate
1.09
EPS Actual
1.12
Post-Earnings Close
$117.91
Earnings Reaction
-4.5%
Xylem opened 2026 with a quarter that was largely in line with expectations rather than a breakout, yet the underlying signals were constructive enough to sustain the full-year organic growth framework. Revenue was flat year-over-year on an organic basis, reflecting deliberate 80/20 portfolio pruning in China and Treatment, while adjusted EPS of $1.12 came in above the $1.09 consensus estimate on the back of disciplined cost management and the benefit of an aggressive share repurchase program. EBITDA margin expanded 20 basis points to 20.6%, a modest but meaningful achievement given the headwinds from mix, lower volumes, and ongoing restructuring costs. The quarter's headline numbers are best understood as a trough in the company's near-term revenue trajectory, with management pointing to normal seasonality and backlog conversion as the engines of a pronounced second-half ramp.
Report generated on Apr 28, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full XYL analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.